Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest

Weight-loss drugs, already widely used for obesity, show promising potential in significantly reducing the risk of developing or dying from breast cancer, according to new studies. Millions currently use these medications, and emerging research presented at the American Society of Clinical Oncology's annual meeting suggests they could play a crucial role in cancer prevention and treatment.

“

While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools.

One analysis revealed that individuals taking GLP-1 medications experienced a 30% lower likelihood of developing breast cancer, the most common cancer globally, compared to those not on the drugs. Furthermore, a separate study indicated that incorporating these weight-loss drugs into standard breast cancer treatment reduced the risk of mortality from the disease by 30%.

Beyond breast cancer, a third study involving patients with breast, lung, bowel, or liver cancer found that those on weight-loss drugs were up to 50% less likely to experience disease progression or spread. These findings were shared at the conference in Chicago, highlighting the multifaceted impact of these drugs.

“

GLP-1 medications are intriguing from a cancer research perspective because they weren’t designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so we’re eager to study them in this context.

GLP-1 medications mimic a natural hormone that regulates blood sugar and appetite. Originally developed for type 2 diabetes, their effectiveness in weight management has led to widespread use. Researchers are intrigued by their potential cancer-fighting properties, as these drugs affect various pathways linked to cancer development. Dr. Elizabeth McDonald of the University of Pennsylvania noted that while observational, the studies add to evidence suggesting these drugs warrant investigation as cancer prevention tools. She added, "Ultimately, we want to find better options to prevent breast cancer. It’s been encouraging to see the survival rates for breast cancer improve over recent decades, and we’d love to see the same gains in prevention."

“

Ultimately, we want to find better options to prevent breast cancer. It’s been encouraging to see the survival rates for breast cancer improve over recent decades, and we’d love to see the same gains in prevention.